With first base editing clinical trial underway, Verve discloses second cardiovascular disease program

Lei Lei Wu

News Reporter

In July, Verve Therapeutics dosed its first patient with a base editing therapy for heterozygous familial hypercholesterolemia (FH), marking the first time base editing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With first base editing clinical trial underway, Verve discloses second cardiovascular disease program

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

With first base edit­ing clin­i­cal tri­al un­der­way, Verve dis­clos­es sec­ond car­dio­vas­cu­lar dis­ease pro­gram

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

With first base editing clinical trial underway, Verve discloses second cardiovascular disease program